Filing Details

Accession Number:
0001562180-21-000913
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-04 16:21:22
Reporting Period:
2021-02-02
Accepted Time:
2021-02-04 16:21:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1590877 Regenxbio Inc. RGNX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1521123 J. Patrick Christmas C/o Regenxbio Inc.
9600 Blackwell Road, Suite 210
Rockville MD 20850
Chief Legal Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-02-02 10,000 $12.10 26,372 No 4 M Direct
Common Stock Disposition 2021-02-02 9,500 $44.77 16,872 No 4 S Direct
Common Stock Disposition 2021-02-02 500 $45.13 16,372 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2021-02-02 10,000 $0.00 10,000 $12.10
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
12,431 2026-08-17 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan.
  2. This transaction was executed in multiple trades at prices ranging from $44.095 to $45.09. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed in multiple trades at prices ranging from $45.13 to $45.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vested in equal monthly installments over the 36 months thereafter.